ArticleBMC cardiovascular disorders2026
Effect of dapagliflozin on left ventricular longitudinal strain and atrioventricular coupling in heart failure with preserved ejection fraction and chronic kidney disease.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSodium-glucose cotransporter 2 inhibitors (SGLT2i), including dapagliflozin, were initially developed for type 2 diabetes mellitus. Despite the established benefits of SGLT2i in heart failure (HF) with preserved ejection fraction (HFpEF), their effects on myocardial deformation (assessed by global longitudinal strain, GLS) and left atrioventricular coupling (quantified by the left atrioventricular coupling index, LACI) in HFpEF patients with concomitant chronic kidney disease (CKD)-hereafter referred to as HFpEF-CKD-remain unclear. This study aimed to evaluate the effects of dapagliflozin on GLS and LACI in this high-risk comorbid population.
methodsThis prospective cohort study enrolled 259 patients with HFpEF-CKD from September 2023 to October 2024. Participants were assigned to two groups: the dapagliflozin group (dapagliflozin 10 mg/day added to conventional HF and CKD therapy without SGLT2i, n = 138) and the control group (conventional HF and CKD therapy without SGLT2i, n = 121). Conventional and speckle-tracking echocardiography were performed at baseline and 6-month follow-up to assess GLS, LACI, left ventricular ejection fraction (LVEF) and left atrial volume (LAV) parameters, including minimal LAV (LAVmin) and LAV index (LAVI).
resultsCompared with controls, dapagliflozin decreased GLS (between-group Δ: -1.34%, 95% CI: -1.72 to -0.97; Cohen's d = 0.875) and reduced LACI (Δ: -0.07, 95% CI: -0.09 to -0.05; Cohen's d = 0.855), both p < 0.001. The dapagliflozin group showed greater reductions in LAV parameters (ΔLAVmin: -6.38 ± 9.06 mL vs. -1.25 ± 3.78 mL, p < 0.001; ΔLAVI: -0.82 ± 1.79 mL/m² vs. -0.43 ± 1.57 mL/m², p = 0.075). LVEF remained stable in both groups (p = 0.264). Multivariable regression analysis confirmed dapagliflozin as an independent predictor for both GLS reduction (B = -1.335, 95% CI: -1.686 to -1.006, p < 0.001) and LACI reduction (B = -0.057, 95% CI: -0.074 to -0.040, p < 0.001).
conclusionsIn patients with HFpEF-CKD, dapagliflozin improves left ventricular longitudinal function and atrioventricular coupling. The superior sensitivity of novel echocardiographic parameters-GLS, LACI, and LAVmin-supports their clinical utility for monitoring early cardiac functional recovery during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.